Atherosclerosis
Conditions
Brief summary
This is a prospective, multi-center imaging study expecting to enroll approximately 1350 patients scheduled for clinically-indicated coronary angiography. Following informed consent, patient will undergo baseline coronary intravascular ultrasound (IVUS) imaging and non-invasive ultrasound imaging of their carotid arteries. Following a 2-year follow-up period, patients will undergo repeat coronary IVUS and standard invasive coronary angiography as well as carotid ultrasound examination. Additionally, patients will be contacted by phone on an annual basis for 5 years to collect cardiovascular and cerebrovascular clinical endpoints. Evaluations of plaque burden will be made using invasive and non invasive imaging tools in order to assess correlations between vascular beds, imaging technologies and main cardiovascular events.
Detailed description
CTA and PET Substudy: A subset of patients enrolled into the main CAIN3 study will undergo a CTA. At sites where both CTA and PET imaging modalities exist, patients will be asked to undergo both tests. The CTA and PET scans can be done separately on 2 imaging beds on different days or performed on the same imaging bed, resulting in a combined CTA and PET scan being done in one scheduled visit. All imaging will be done within 90 days after the follow up IVUS. The choice of radiotracer used (NaF or FDG) for PET imaging will be dependent upon site and availability on the day of the scan. A total of 120 patients will be enrolled in this substudy with approximately 50-60 undergoing CTA and PET.
Interventions
None listed
Sponsors
Canadian Institutes of Health Research (CIHR)
Canadian Atherosclerosis Imaging Network
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients over the age of 18 years. * Patients scheduled for clinically indicated coronary angiography and possible ad hoc percutaneous coronary intervention (PCI) will be evaluated before their scheduled procedure. * Written informed consent (approved by the Institutional Review Board \[IRB\]/Independent Ethics Committee \[IEC\]) obtained prior to any study specific procedures. * Patients considered to be stable at enrollment (at the discretion of the investigator) are eligible provided they meet all other entry criteria. * Angiogram meeting qualifying criteria
Exclusion criteria
* Women of childbearing potential (women who are not surgically sterile or postmenopausal defined as amenorrhea for \>12 months) who refuse to undergo a urine or serum pregnancy test immediately prior to baseline and repeat imaging evaluations The urine or serum pregnancy test must be negative prior to imaging evaluations. * Previous coronary artery bypass graft (CABG) surgery or probable need for CABG in the next 24 months. * Patients who have symptomatic congestive heart failure (CHF) (New York Heart Association \[NYHA\] Class III or IV) at baseline. * Patients with clinically significant valvular heart disease likely to require surgical repair or replacement during the treatment period of the study * Any clinically significant medical condition or presence of any laboratory abnormality that is considered by the investigator to be clinically important and could interfere with the conduct of the study. * The presence of severe liver disease as defined by the presence of cirrhosis, chronic active hepatitis, or chronic jaundice with hyperbilirubinemia, * Patients with eGFR \< 45 ml/min prior to baseline imaging procedures, or with nephrotic syndrome * Patients with a life expectancy less than 2 years. * History of malignancy (except for curatively treated basal cell or squamous cell carcinoma of the skin) during the 3 years prior to the screening. * Unable or unwilling to comply with protocol requirements, or deemed by the investigator to be unfit for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| co-primary outcome measure - Nominal change from baseline in percent atheroma volume | 2 years | intravascular ultrasound measure |
| co-primary outcome measure - nominal change from baseline in carotid IMT | 2 years | 2D B-mode carotid ultrasound measure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cardiovascular morbidity and mortality | 5 years | as adjudicated by a Clinical Endpoint Committee |
Countries
Canada
Outcome results
None listed